NDUFS8
ENSG00000110717
Target class
Enzyme
Chromosome
11
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFS8
- Gene name
- NADH:ubiquinone oxidoreductase core subunit S8
- Gene symbol
- NDUFS8
- Protein name
- NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial (EC 7.1.1.2) (Complex I-23kD) (CI-23kD) (NADH-ubiquinone oxidoreductase 23 kDa subunit) (TYKY subunit)
- TYKY
- CI-23k
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits|MicroRNA protein coding host genes
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 151.73
- Tissue specificity (Gini)
- 0.162
- Tissue specificity (tau)
- 0.58
- KEGG gene identifiers
- hsa:4728
- Protein interaction confidence
- 0.902797
- Protein interaction partners
- 158
- R-HSA-611105
- R-HSA-6799198
- End position
- 68036647
- Start position
- 68030617
- Chromosome
- 11
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Mitochondria
- PubMed 12611891
- PubMed 9666055
- Tissue specificity (tau)
- 0.580297
- Expression inequality (Gini)
- 0.162146
Expression in transcripts per million
- Adrenal Gland
- 151.73
- Heart - Left Ventricle
- 104.02
- Heart - Atrial Appendage
- 101.51
- Muscle - Skeletal
- 94.77
- Pituitary
- 93.77
Expression in transcripts per million
- Adrenal Gland151.73
- Heart - Left Ventricle104.02
- Heart - Atrial Appendage101.51
- Muscle - Skeletal94.77
- Pituitary93.77
- Colon - Sigmoid90.53
- Esophagus - Muscularis88.36
- Testis87.52
- Prostate85.89
- Esophagus - Gastroesophageal Junction84.5
- Thyroid84.2
- Kidney - Medulla82.92
- Brain - Nucleus accumbens (basal ganglia)70.08
- Uterus69.89
- Artery - Coronary69.23
- Cervix - Ectocervix67.4
- Artery - Aorta67.29
- Fallopian Tube66.8
- Cells - Cultured fibroblasts66.02
- Kidney - Cortex65.49
- Brain - Caudate (basal ganglia)64.64
- Brain - Frontal Cortex (BA9)64.58
- Brain - Cerebellar Hemisphere64.55
- Cervix - Endocervix64.43
- Colon - Transverse63.45
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0032981
- GO:0005739
- GO:0005743
- GO:0005759
- GO:0045271
- GO:0003954
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor